To reach the next value inflection
LicenseRx asset brief
Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs
Probability of Success
16% · grade B · Medium data confidence
Model PoS 16% (grade B, medium data confidence). Strongest signals: IP position, Indication pull. Biggest drag: Competitive whitespace.
Data maturity (22%)
45
Early / Discovery; human data, clinical reference.
IP position (16%)
88
Issued/granted patent on record.
Modality feasibility (14%)
65
Modality unclear from public data -- assumed average development risk.
Indication pull (14%)
76
Neurology -- active buyer appetite.
Competitive whitespace (12%)
68
Average room to differentiate vs. incumbents.
Translational evidence (12%)
70
Public evidence mentions: clinical, human, patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →